Gelonghui, October 24th – Hengrui Pharma (01276.HK) announced that recently its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received notification from the National Medical Products Administration (hereinafter referred to as “NMPA”), approving the listing of the company’s Sodium Gluconate and Metformin Hydrochloride Sustained-Release Tablets (I), (II) (HR20031 tablets). This product is China's first domestically developed oral triple-combination fixed-dose combination antidiabetic medication. The relevant details are hereby announced as follows:
Basic Information of the Drug: Drug Name: Sodium Gluconate and Metformin Hydrochloride Sustained-Release Tablets (I), (II)
Dosage Form: Tablets; Specifications: 5/50/750mg, 10/100/1000mg; Registration Category: Chemical Medicine Class 2.3
Application Number: CXHS2300099, CXHS2300100
Prescription Drug/Over-the-Counter Drug: Prescription Drug
Approved Indication: In conjunction with dietary control and exercise, this product is used to improve glycemic control in adult patients with type 2 diabetes whose blood glucose is inadequately controlled by metformin hydrochloride.
